Skip to main content
    C

    Cronos Group Inc (CRON)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.27
    -0.11 (-3.25%)

    Market Cap: $1.24B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cronos Group Inc (CRON) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Cronos Group reported EPS of $0.04, above the $0.03 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    35%(13/37)
    Avg Surprise
    +18.02%
    Streak
    3 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.04
    Range$0.03 - $0.05
    5 analysts
    Revenue Consensus
    $68.00M
    Range$62.92M - $71.50M
    6 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.07
    Range$0.04 - $0.09
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.08-21.9%
    Current$0.07
    Revenue Consensus
    $95.50M
    Range$87.73M - $100.94M
    3 analysts

    Next Report

    CRON's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    CRON Earnings Call

    The latest CRON earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, CRON beat 13, missed 19 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $83.90M, up 71.8% from $48.83M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.04$0.03$0.03 - $0.07+33.33%Beat-60.0%30 up, 1 downNov 5, 2026$83.90M
    Jun 30, 2026$0.03$0.01$0.01 - $0.01+200.00%BeatN/A20 up, 1 downAug 6, 2026$53.01M
    Mar 31, 2026$0.05$0.01$0.00 - $0.01+400.00%Beat+66.7%20 up, 1 downMay 11, 2026$45.21M
    Dec 31, 2025$0.00$0.01$0.01 - $0.03-147.00%Miss-103.0%30 up, 0 downFeb 26, 2026$32.04M
    Sep 30, 2025$0.10$0.02N/A+400.00%Beat+233.3%10 up, 0 downNov 6, 2025$48.83M
    Jun 30, 2025-$0.10-$0.02N/A-400.00%MissN/AN/A0 up, 0 downAug 7, 2025$33.45M
    Mar 31, 2025$0.03$0.00N/A+957.14%BeatN/AN/A0 up, 0 downMay 8, 2025$32.26M
    Dec 31, 2024$0.16-$0.01N/AN/AN/AN/AN/A0 up, 0 downFeb 27, 2025$30.30M
    Sep 30, 2024$0.03-$0.01-$0.02 - $0.00+400.00%BeatN/A30 up, 0 downNov 12, 2024$34.26M
    Jun 30, 2024-$0.02-$0.07N/A+71.43%BeatN/A40 up, 0 downAug 8, 2024$27.76M
    Mar 31, 2024-$0.01-$0.01-$0.02 - -$0.010.00%In lineN/A30 up, 0 downMay 9, 2024$25.29M
    Dec 31, 2023-$0.05-$0.01-$0.02 - -$0.01-400.00%MissN/A20 up, 0 downFeb 29, 2024$23.91M
    Sep 30, 2023-$0.02-$0.04N/A+50.00%BeatN/A40 up, 0 downNov 8, 2023$24.81M
    Jun 30, 2023-$0.03-$0.05-$0.05 - -$0.02+40.00%BeatN/A50 up, 0 downAug 8, 2023$19.02M
    Mar 31, 2023-$0.03-$0.05-$0.07 - -$0.02+40.00%BeatN/A40 up, 0 downMay 9, 2023$19.50M
    Dec 31, 2022-$0.21-$0.05-$0.07 - -$0.03-320.00%MissN/A40 up, 0 downFeb 28, 2023$19.70M
    Sep 30, 2022-$0.09-$0.07-$0.07 - -$0.04-28.57%Miss-142.9%41 up, 0 downNov 7, 2022$20.41M
    Jun 30, 2022-$0.07-$0.07-$0.07 - -$0.030.00%In lineN/A30 up, 0 downAug 9, 2022$21.60M
    Mar 31, 2022-$0.11-$0.10N/A-10.00%MissN/A40 up, 0 downMay 10, 2022$25.03M
    Dec 31, 2021-$0.11-$0.13N/A+15.38%BeatN/A32 up, 0 downFeb 18, 2022$15.92M
    Sep 30, 2021$0.21-$0.10-$0.12 - -$0.10+310.00%BeatN/A40 up, 0 downSep 30, 2021$20.41M
    Jun 30, 2021-$0.14-$0.08N/A-75.00%MissN/AN/AN/AAug 6, 2021$15.62M
    Mar 31, 2021-$0.14-$0.11N/A-27.27%MissN/AN/AN/AMay 7, 2021$12.61M
    Dec 31, 2020-$0.31-$0.07N/A-342.86%Miss-247.6%N/AN/AFeb 26, 2021$24.68M
    Sep 30, 2020-$0.13-$0.05N/A-160.00%MissN/AN/AN/ANov 5, 2020$11.36M
    Jun 30, 2020-$0.09-$0.07N/A-28.57%MissN/AN/AN/AAug 6, 2020$9.88M
    Mar 31, 2020-$0.10-$0.09N/A-11.11%MissN/AN/AN/AMay 8, 2020$8.43M
    Dec 31, 2019$0.21-$0.04N/A+625.00%BeatN/AN/AN/AMar 30, 2020$7.92M
    Sep 30, 2019-$0.07-$0.04N/A-75.00%MissN/AN/AN/ANov 12, 2019$6.27M
    Jun 30, 2019-$0.04-$0.02N/A-100.00%MissN/AN/AN/AAug 8, 2019$8.06M
    Mar 31, 2019-$0.06-$0.03N/A-100.00%MissN/AN/AN/AMay 9, 2019$3.39M
    Dec 31, 2018-$0.05$0.02N/A-350.00%MissN/AN/AN/AMar 26, 2019$3.71M
    Sep 30, 2018-$0.04-$0.02N/A-100.00%MissN/AN/AN/ANov 13, 2018$2.91M
    Jun 30, 2018-$0.02-$0.01N/A-100.00%MissN/AN/AN/AAug 14, 2018$2.58M
    Mar 31, 2018-$0.01-$0.01N/A0.00%In lineN/AN/AN/AMay 15, 2018$2.28M
    Sep 30, 2017-$0.01-$0.01N/A0.00%In lineN/AN/AN/ANov 29, 2017$1.31M
    Jun 30, 2017-$0.01-$0.01N/A0.00%In lineN/AN/AN/AAug 28, 2017$643000
    Mar 31, 2017-$0.02-$0.01N/A-100.00%MissN/AN/AN/AMay 1, 2017$514000
    Dec 31, 2016$0.01N/AN/AN/AN/AN/AN/AN/AFeb 17, 2017$1.97M
    Sep 30, 2016$0.00N/AN/AN/AN/AN/AN/AN/ANov 30, 2016N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.03, down 84.1% from the year before. It was -$0.03 for the year ended Dec 31, 2016, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.03-84.1%
    Dec 31, 2024$0.16N/A
    Dec 31, 2023-$0.13N/A
    Dec 31, 2022-$0.48N/A
    Dec 31, 2021-$0.18N/A
    Dec 31, 2020-$0.63-1675.0%
    Dec 31, 2019$0.04N/A
    Dec 31, 2018-$0.16N/A
    Dec 31, 2016-$0.03N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,600 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,6467
    2026Q2Jun 30, 20263,2428
    2025Q4Dec 31, 20254,1848
    2025Q3Sep 30, 20252,1465
    2025Q2Jun 30, 20251,7644
    2025Q1Mar 31, 20252,4025
    2024Q4Dec 31, 20242,6084
    2024Q3Sep 30, 20243,0256

    2026Q3 Earnings Call

    Opening remarks

    Harrison Aaron Senior Director, Investor Relations and Corporate Development Thank you, Stephanie, and thank you for joining us today to review Cronos' 2026 Q3 financial and business performance. Today, I am joined by our Chairman, President, and CEO, Mike Gorenstein, and our CFO, Anna Shlimak. Cronos issued a news release announcing our financial results this morning, which is filed on our EDGAR and SEDAR profiles. This information and the prepared remarks will also be posted on our website under Investor Relations. Before I turn the call over to Mike, let me remind you that we may make forward-looking statements and refer to non-GAAP financial measures during this call. These forward-looking statements are based on management's current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings that are available on our website, by which any forward-looking statements made during this call are qualified in their entirety. Information about non-GAAP financial measures, including reconciliations to U.S. GAAP, can also be found in the earnings materials that are available on our website. Lastly, we will be making statements regarding market share information throughout this conference call, and unless otherwise stated, all market share data is provided by HiFyre. We will now make prepared remarks, and then we'll move to a question-and-answer session. With that, I'll pass it over to Cronos' Chairman, President, and CEO, Mike Gorenstein.

    Mike Gorenstein Chairman, President, and CEO Thanks, Harrison. Cronos delivered an outstanding third quarter, organically achieving records across net revenue, gross profit, and Adjusted EBITDA, reflecting the successful execution of our borderless product strategy across each region in which we operate. Starting with Israel, Cronos delivered its 11th consecutive quarter of record net revenue, growing 33% year-over-year, or 19% growth on a constant currency basis, with the PEACE NATURALS brand reinforcing its leadership position based on pharmacy data collected by Cronos. Our value brand, LIT, also drove growth in the quarter. Turning to Canada, we delivered record net revenue, with our brands generating 41% year-over-year retail sales growth relative to industry-wide sales growth of 1%. The Spinach brand posted another standout quarter, with its market-leading share gains underscoring the effectiveness of our innovation engine. In Canada, Spinach maintained its number one position in vapes for the third consecutive quarter, with total vape market share expanding to 11.4%. Within the vape cartridge subcategory, Spinach held its number one position for the fourth consecutive quarter, with market share expanding to 12.1%. In the all-in-one vape subcategory, Spinach share expanded to 10.2%, as our PUFFERZ all-in-one innovation continues to gain market traction.

    Frequently Asked Questions About CRON

    Did CRON beat earnings estimates last quarter?

    Yes. Cronos Group reported EPS of $0.04 for the quarter ended Sep 30, 2026, above the $0.03 estimate, a 33.33% surprise.

    What EPS do analysts expect from CRON next quarter?

    The consensus EPS estimate for Cronos Group for the quarter ending Dec 31, 2026 is $0.04 from 5 analysts, with estimates from $0.03 to $0.05.

    How often does CRON beat earnings estimates?

    Cronos Group beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +230.43%.